Loma Linda University

TheScholarsRepository@LLU: Digital Archive of Research,
Scholarship & Creative Works
Loma Linda University Electronic Theses, Dissertations & Projects

6-2017

A Novel Population of Cardiovascular Progenitors
Persist in Neonates as Mesendodermal Cells
Julia Kim

Follow this and additional works at: http://scholarsrepository.llu.edu/etd
Part of the Biochemistry Commons, and the Medical Biochemistry Commons
Recommended Citation
Kim, Julia, "A Novel Population of Cardiovascular Progenitors Persist in Neonates as Mesendodermal Cells" (2017). Loma Linda
University Electronic Theses, Dissertations & Projects. 484.
http://scholarsrepository.llu.edu/etd/484

This Thesis is brought to you for free and open access by TheScholarsRepository@LLU: Digital Archive of Research, Scholarship & Creative Works. It
has been accepted for inclusion in Loma Linda University Electronic Theses, Dissertations & Projects by an authorized administrator of
TheScholarsRepository@LLU: Digital Archive of Research, Scholarship & Creative Works. For more information, please contact
scholarsrepository@llu.edu.

LOMA LINDA UNIVERSITY
School of Medicine
in conjunction with the
Faculty of Graduate Studies

____________________

A Novel Population of Cardiovascular Progenitors Persist in Neonates
as Mesendodermal Cells
by

Julia Kim

____________________

A Thesis submitted in partial satisfaction of
the requirements for the degree
Master of Science in Biochemistry

____________________

June 2017

© 2017
Julia Kim
All Rights Reserved

Each person whose signature appears below certifies that this thesis in his/her opinion is
adequate, in scope and quality, as a thesis for the degree Master of Science.

, Chairperson
Mary Kearns-Jonker, Associate Professor of Anatomy and Pathology

Michael Pecaut, Professor of Radiation Research

Nathan Wall, Associate Professor of Biochemistry

iii

ACKNOWLEDGEMENTS

I would like to express my deepest gratitude to Dr. Kearns-Jonker, who has
generously provided me with the opportunities to pursue my passion and excel in my
academic endeavors. Thank you for challenging me to go beyond the bare minimum, for
your careful instruction, and your guidance through countless experiments and
presentations. I hope that my contribution to your lab has been as enjoyable for you as it
has for me.
I would also like to thank my committee members for their advice and direction. I
have appreciated your integral scientific contributions and insightful critique towards my
academic endeavors.
To members of the Kearns-Jonker laboratory, I would like to extend a special
thanks. Thank you, for the technical and moral support you have offered me throughout
my time in the lab, for celebrating with me in my triumphs and encouraging me in
moments of defeat. I will cherish the memories we have made and laughter we shared.
To my family and friends, your words of encouragement and support have
provided me with strength and comfort. Thank you for believing in me during times I
failed to believe in myself. Finally, I would like to thank God, for revealing His unending
love and wisdom to me as I studied the intricacies of His creation.

iv

CONTENT

Approval Page .................................................................................................................... iii
Acknowledgements ............................................................................................................ iv
Table of Contents .................................................................................................................v
List of Figures .................................................................................................................... vi
List of Tables .................................................................................................................... vii
List of Abbreviations ....................................................................................................... viii
Abstract ................................................................................................................................x
Chapter
1. Introduction ..............................................................................................................1
2. Materials and Methods .............................................................................................8
Ethics Statement/Maintenance of CPCs ............................................................8
Neonatal CPC Culture and in vitro Differentiation ....................................... 8-9
RNA Extraction ...............................................................................................10
qRT-PCR Analysis...........................................................................................10
Flow Cytometry ...............................................................................................10
Statistical Analysis ...........................................................................................11
3. Results ....................................................................................................................12
Human Neonatal CPCs Express a Distinct Set of Early Developmental
Markers ............................................................................................................12
Differentiation of an ISL1+/c-KIT+ and MESP1+ Neonatal CPC into
the Cardiac Lineage .........................................................................................15
A Neonatal CPC Co-Expressing ISL1, c-KIT, KDR and MESP1
Differentiates into a Mature Osteoblast Phenotype .........................................18
4. Discussion ..............................................................................................................23
References ..........................................................................................................................26
Supplemental Table ...........................................................................................................36

v

FIGURES

Figures

Page

1. Osteogenic differentiation by ascorbic acid, -glycerophosphate, and
dexamethasone treatment .......................................................................................10
2. mRNA analysis of molecular markers associated with mesoderm,
precardiac mesoderm, and cardiac progenitors ......................................................14
3. Summary of the stage-specific expression of molecular markers associated
with cardiovascular development .........................................................................15
4. Differentiation of ISL1+/c-KIT+/MESP1+/KDR+ human neonatal CPC into
cardiomyocytes ......................................................................................................17
5. Tube formation by the ISL1+/c-KIT+/KDR+ and MESP1+ neonatal CPC
clone verifies differentiation along the endothelial cell lineage ............................18
6. Timeline of neonatal CPC differentiation into osteoblasts ....................................19
7. Neonatal CPC co-expressing ISL1, c-KIT, KDR, and MESP1 treated with
osteogenic supplements for 7 days showed enhanced expression of
osteogenic markers.................................................................................................21
8. The ISL1+/c-KIT+/KDR+ and MESP1+ Neonatal CPC treated with
osteogenic supplements for 14-16 days showed enhanced expression of
late-stage osteoblast differentiation marker, osteocalcin. ......................................22
9. The ISL1+/c-KIT+/KDR+ and MESP1+ Neonatal CPC treated with
osteogenic supplements for 14-16 days showed enhanced expression
osteocalcin by flow cytometry ...............................................................................23

vi

TABLES

Tables

Page

1. Animal and human studies of next-generation cell-based regenerative
therapies ...................................................................................................................5
2. List of primers used to detect gene expression by qRT-PCR ................................36

vii

ABBREVIATIONS
ALPL

Alkaline phosphatase

c-KIT

KIT proto-oncogene receptor tyrosine kinase

CM

Cardiomyocyte

COL1A1

Collagen type 1

CPC

Cardiovascular progenitor cell

EC

Endothelial cell

EGFP

Enhanced green fluorescent protein

EOMES

Eomesdermin

FHF

First heart field

Flk-1

Fetal liver kinase-1

FS

Fractional shortening

GATA4

GATA binding protein 4

GSC

Goosecoid

HCN4

Hyperpolarization Activated Cyclic Nucleotide Gated
Potassium Channel 4

hCO

Human cardiac organoid

hESC

Human embryonic stem cell

ISL1

Islet-1

KDR

Kinase insert domain receptor

LVED

Left ventricular end-diastole

LVEF

Left ventricular ejection fraction

MESP1

Mesoderm posterior homolog 1

MIXL1

Mix paired-like homeobox

viii

MLC2V

Myosin light chain 2

MPC

Multipotential progenitor cell

NANOG

Nanog homeobox

NKX2-5

NK2 homeobox 5

OCN

Osteocalcin

OCT-4

Octamer-binding protein 4

OPN

Osteopontin

PDGFR

Platelet derived growth factor receptor

RUNX2

Runt related transcription factor 2

SHF

Second heart field

SM

Smooth muscle actin

SMA

Smooth muscle cell

SOX2

SRY-box 2

T

Brachyury

TBX5

T-box 5

TGF-

Transforming growth factor, beta

TNNT2

Troponin T2

vWF

Von Willebrand factor

ix

ABSTRACT OF THE THESIS
The Mesendodermal Stage of Development is Sustained within a Novel Population of
Human Neonatal Cardiovascular Progenitor Cells
by
Julia Kim
Master of Science, Graduate Program in Biochemistry
Loma Linda University, June 2017
Dr. Mary Kearns-Jonker, Chairperson

The rise in mortality due to cardiovascular disease has increased the need to
develop an efficient regenerative therapeutic for heart failure. Numerous cell-based
therapies have been investigated for myocardial regeneration; however, an optimal
progenitor has yet to be discovered. Identifying a resident cell population with enhanced
ability to differentiate into multiple lineages would greatly contribute to the field of stem
cell-based regenerative therapy. Evidence suggests that endogenous cardiovascular
progenitor cells (CPCs) that have been isolated from the heart itself express ISL1, KDR,
and MESP1, and are capable of differentiating into all major cardiac lineages. The earlier
developmental stage at which endogenous CPCs reside may be associated with enhanced
multipotency and differentiation capacity. A clonal population of human neonatal CPCs
expressing markers of early cardiovascular development was therefore selected for
analysis. Based upon recent reports of differentiation into osteoblasts by cells expressing
ISL1, we performed differentiation of the selected neonatal CPC into cardiovascular
lineages as well as the mesodermal derivative, osteoblasts. Gene expression analysis and
flow cytometry demonstrated differentiation into both cardiovascular and osteoblast
lineages. To further address the relationship between an earlier developmental stage and

x

differentiation capability, we measured the expression of mesendodermal regulatory
markers, and discovered that this population of progenitor cells may reside earlier in
development than previously recognized. These results suggest that neonatal
cardiovascular progenitors expressing transcripts of the mesendoderm persist within the
newborn human heart, exhibit enhanced differentiation capacity into various mesodermal
lineages, and can be expanded for further assessment of functional and regenerative
ability
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CHAPTER ONE
INTRODUCTION

For the last fifteen years, cardiovascular disease has been the leading cause of
death worldwide1. Heart failure is predominantly associated with the loss of
cardiomyocyte number and function following myocardial infarction, leading to
cardiomyocyte hypertrophy, pathological remodeling of the heart, and ultimately to
cardiac dysfunction (Lam et al., 2009). The heart’s limited regenerative capacity has
prompted the investigation of stem cell-based therapeutics for cardiac repair (Cyganek et
al., 2013; Garbern et al., 2013; Karra et al., 2008). Among the myriad of stem cell
populations that have been investigated, endogenous cardiac stem cells show great
promise for the treatment of heart failure (Fuentes et al., 2013; Mayfield et al., 2014;
Nadal-Ginard et al., 2014). However, the origins of these progenitor cells and the
mechanisms governing lineage specification and differentiation have yet to be fully
elucidated (Chong et al., 2014). A comprehensive understanding of the identity and
differentiation capacity of endogenous CPCs would greatly advance the field of stem
cell-based regenerative therapy.
The heart has long been thought to originate from two bilateral heart fields during
early gastrulation (Brand, 2003); whereby the first heart field (FHF) contributes to the
formation of the left ventricle and atria, and the second heart field (SHF) contributes
predominantly to the right ventricle, outflow tract, and parts of the atria (Bruneau, 2013).
Recently, however, an alternative school of thought regarding the origin of the heart has
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Available at: http://www.who.int/mediacentre/factsheets/fs310/en/ Accessed March 4, 2017.
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developed. Several studies have provided key insight into population(s) of multipotent
cardiovascular progenitors that exist during the early stages of embryonic development,
suggesting that the heart may actually be derived from a single primordial precursor with
the ability to differentiate into all cardiac lineages rather than two separate progenitor
populations (Abu-Issa et al., 2004; Meilhac et al., 2004; Moorman et al., 2007). Emerging
evidence of an inverse relationship between the developmental stage and regenerative
capacity of cardiac progenitors supports the need to investigate endogenous
cardiovascular cell populations that reside at early stages of development (Porrello et al.,
2011; Fuentes et al., 2013; Jaszczak et al., 2016).
Although little is known regarding the molecular identity of a single primordial
precursor, advances in cell fate-mapping techniques revealed that CPC populations may
be found prior to formation of the primitive streak in the developing mouse embryo
(Audo-Boucher et al., 2000). Various signaling molecules and transcription factors play
critical roles in promoting differentiation of CPCs that are present during this “prestreak” stage. Expression of the molecular markers Mesp1, Brachyury (T), and Flk-1
(also known as KDR in humans) have been suggested to mark a population of cardiogenic
primordial cells during murine embryonic development that are capable of differentiating
into functional cardiomyocytes, endothelial, and smooth muscle cells (Kattman et al.,
2006; Meilhac et al., 2014; Chiapparo et al., 2016; Liu et al., 2016). The temporal
appearance of Brachyury and Mesp1 have been shown to regulate the specification of the
primitive streak (Bondue et al., 2008). Furthermore, knock out studies in mice support
evidence suggesting that Mesp1 and Flk-1 are required for proper differentiation into the
cardiovascular lineage (Saga et al., 1999; Kitajima et al., 2000; Abunnaja et al., 2014).
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Analogous studies on human embryonic stem cells (hESCs) have revealed that
MESP1 and KDR are expressed in human CPCs and are essential for heart formation
(Yang et al., 2008; Ardehali et al., 2013). Cardiovascular progenitors expressing MESP1
contribute to both first and second heart field derivatives (Bondue et al., 2010; Lescroart
et al., 2014), and MESP1-null hearts lead to abnormalities during heart morphogenesis,
resulting in cardia bifida. (Saga et al., 1996; 1999). Piccini and colleagues published data
demonstrating that MESP1 expression peaks at day 2 of hESC differentiation, thereby
indicating early and temporal expression of MESP1 in cardiac development (Piccini et
al., 2016). Den Hartogh and Passier investigated the differentiation events of
cardiovascular development in a dual MESP1mCherry/w-NKX2-5eGFP/w reporter line
generated from hESCs and reported the gene expression profile of MESP1-positive cells
compared to that of MESP1-negative cells. Results from this study revealed that early
cardiac genes were enriched during peak expression of MESP1 (Den Hartogh et al.,
2014). These results are consistent with earlier findings that MESP1 expression occurs at
early stages of development and serves as a key regulator of cardiovascular
differentiation. Identifying a population of CPCs with multipotential capability would
provide access to an optimal cell source for regenerating vital organs such as the heart.
There has been an increasing emphasis on understanding the molecular role of
MESP1 and KDR in the context of cardiovascular development; and more specifically,
their interactions with cardiac transcription factors, such as ISL1 (Solloway et al., 2003;
Kattman et al., 2007). Interestingly, ISL1 has been reported to be co-expressed with
MESP1 in a subset of early MESP1-expressing cells (Bondue et al., 2008 & 2011). The
LIM-homeodomain transcription factor, ISLET1, plays a critical role in cardiovascular
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development (Laugwitz et al., 2005; Moretti et al., 2006, Wu et al., 2006). ISL1 marks a
population of CPCs capable of giving rise to all cardiac lineages (Moretti et al., 2006; Ma
et al., 2008; Fonoudi et al., 2013), and Isl1-null hearts in mice fail to undergo looping
morphogenesis and are completely devoid of major components of the heart, including
the outflow tract, right ventricle, and parts of the atria (Cai et al., 2003). ISL1 expression
is required for the survival, proliferation and migration of progenitor cells into the cardiac
tube during heart development (Laugwitz et al., 2008). A recent report on the engraftment
of human ISL1-CPC spheroids after myocardial infarction in murine hearts showed that
mice treated with ISL1-CPC spheroids exhibited reduced infarct area, increased blood
vessel formation, and increased left ventricular contractile function compared to control
animals (Bartulos et al., 2016). These results indicate that an MESP1+/ISL1+ CPC
population is capable of demonstrating multipotential capability and could serve as a
promising candidate for stem cell-based regenerative therapeutics.
The efficacy of regeneration by CPCs expressing markers that are prevalent at
varying stages of development have been investigated in both murine and human hearts.
Studies in rodent hearts revealed a developmental stage-dependent discrepancy, whereby
cell sources expressing early developmental markers demonstrated greater increases in
regenerative capability than cells expressing late-stage markers (Table 1). Furthermore,
cardiovascular progenitors expressing early developmental markers such as KDR,
PDGFR, and ISL1 demonstrated better functional outcomes as measured by fractional
shortening and/or ejection fraction (Table 1). Comparable results were shown in both
mouse and human hearts following myocardial infarction. Such findings support the
concept that early cardiovascular stem cells are better candidates for stem cell-based

4

therapies than late-stage cardiovascular stem cells. Moreover, CPCs provide a promising
cell source for regenerative therapies due to minimal risk for teratoma formation
following engraftment of cardiomyocytes relative to hESCs (Ardehali et al., 2013; Shiba
et al., 2012; Chong et al., 2014; Harman et al., 2016).

Table 1. Animal and human studies of next-generation cell-based regenerative therapies.
Study

Dev Stage

Rodent
(Fernandes et al., 2015)

Early

Rodent
(Li et al., 2017)

Early

Rodent
(Tang et al.., 2010)

Late

Cell source

Clinical effects

KDR+/PDGFR+ hESC-derived CPCs +28% FS
(at 28 days)
Isl1+ CPCs

+20% LVEF
(at 28 days)

c-Kit+/EGFP+ CPCs

+4% FS
+8% LVEF
(at 35 days)

Human
(Menasché et al., 2015)

Early

Human: CADUCEUS
(Makkar et al., 2012)

Late

Human: SCIPIO
(Bolli et al., 2011)

Late

Isl1+/SSEA-1+ hESC-derived CPCs

+10% LVEF
(at 3 months)

c-Kit+ cardiospheres

+2% LVEF
(at 6 months)

c-Kit+ Adult CPCs

+12.3 ± 2.1%
LVEF
(at 4 months)

Abbreviations: FS, fractional shortening; LVEF, left ventriclular ejection fraction;
LVED, left ventricle at end-diastole volume.

Among the wide array of cell populations studied within the field of stem cellbased therapy for heart repair, endogenous CPCs from neonatal sources are considered to
be the most promising. Cardiomyocyte exchange has been shown to occur more often in
early childhood with a gradual decline throughout life (Bergmann et al., 2015), and
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compelling results on the functional recovery of the human neonatal heart have been
reported by numerous case studies (Saker et al., 1997; Farooqi et al., 2012; Cesna et al.,
2013; Haubner et al., 2016). Recent analysis of the injury response of human cardiac
organoids (hCOs) revealed that, following cyroinjury in vitro, hCOs resembled neonatallike human cardiac tissue and underwent functional recovery in the absence of fibrosis or
hypertrophy (Voges et al., 2017). Furthermore, neonatal CPCs demonstrate enhanced
capacity for regulatory processes critical for regeneration, including proliferation,
migration, and invasion (Fuentes et al., 2013; Mollova et al., 2013). MicroRNA analysis
of neonatal CPCs co-expressing ISL1 and c-KIT, a population that is the focus of work
done in our laboratory, revealed significant upregulation of transcripts that promote cell
invasion compared to adult CPCs, and distinct clonal populations of neonatal CPCs
expressed moderate to high levels of the pre-cardiac mesoderm markers KDR and
PDGFR (Fuentes et al., 2013). Thus, this neonatal ISL1+/c-KIT+ population expressing
markers of early cardiac development could serve as a cell source similar to that of a
single primordial precursor with enhanced efficacy for heart repair.
Stem cells expressing ISL1 have been shown to be capable of differentiation into
an osteoblastic phenotype (Eberhardt et al., 2006; Itzhaki-Alfia et al., 2009; Akiyama et
al., 2014). MESP1 expressing cells can differentiate into mesodermal derivatives
including skeletal muscle and bone (Chan et al., 2013; Bondue et al., 2011). Emerging
evidence suggests that MESP1 plays an important regulatory role in development (Liu,
2017). Moreover, studies show that cells at early stages of development adopt their fate
by location (Meilhac et al., 2014). Understanding the molecular properties contributing to
mutipotency, commitment, and differentiation in cells that express all of these early
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transcription factors is therefore necessary to identify the specific population of neonatal
CPCs that may serve as optimal candidates for cardiac repair.
The hunt for an ultimate progenitor has begun. With the rise in mortality due to
heart disease, there is a growing need to develop an efficient regenerative therapeutic.
The field of stem cell-based therapy has performed extensive analyses on numerous cell
populations with limited efficacy. Studies reveal that endogenous human neonatal CPCs
possess greater potential as a source of cells to regenerate the heart compared to adult
CPCs (Simpson et al., 2012; Fuentes et al., 2013). ISL1, MESP1, and KDR are expressed
on CPCs that can differentiate efficiently into all cardiovascular lineages (Moretti et al.,
2006; Lescroart et al., 2014; Bulatovic et al., 2016). Furthermore, neonatal CPCs coexpressing ISL1, MESP1, KDR, as well as c-KIT have been isolated in our laboratory and
may represent a candidate with multipotential differentiation capability as well as
enhanced regenerative function. Thus, the work proposed in my specific aims has been
directed towards identifying whether or not this ISL1, MESP1, KDR, and c-KIT
expressing clonal population of human neonatal CPCs isolated by our laboratory has
multipotential differentiation capability. Results from these studies will determine the
capability of these stem cells to differentiate into cardiac as well as osteoblast lineages.
Additionally, findings from this study will provide innovative and essential information
that will contribute to better functional outcomes in future stem-cell based therapeutic
studies for patients with heart disease.
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CHAPTER TWO
MATERIALS AND METHODS

Ethics Statement/ Maintenance of CPCs
The Institutional Review Board of Loma Linda University approved the protocol
for the use of discarded tissue during cardiovascular surgery, without identifiable
information, for this study with a waiver of informed consent. Cell isolation and
expansion protocols were performed in previous studies for further use in the laboratory
(Fuentes et al., 2013). In brief, discarded atrial cardiac tissue obtained during
cardiovascular surgery of human neonates was cut into ~1mm3 segments and collagenase
digested (Roche Applied Science, Indianapolis, IN) for 2 hours at 37C at a proportion of
1:2.5 tissue volume vs. collagenase. This solution was passed through a 40m cell
strainer (Smits et al., 2009) and resulting cells were cloned by limiting dilution at a
concentration of 0.8 cells per well to create clonal populations.

Neonatal CPC Culture and in vitro Differentiation
Neonatal CPCs were cultured in 6-well plates coated with 0.1% gelatin. Control
cells were cultured in CPC growth medium and passaged using 0.25% trypsin solution
upon reaching 80% confluency. Cardiomyocyte differentiation of cardiac progenitor cells
was performed by treatment with 5-azacytidine, ascorbic acid, and TGF- in
differentiation media for 14 days (Smits et al., 2009). In brief, CPC growth medium was
exchanged for differentiation medium once cells reached >80% confluency. After 6-8
hours of changing media, 5µM 5-azacytidine was added directly to the cells for three
consecutive days with a media change on day 4. Six days after the start of the
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cardiomyocyte differentiation assay, 1000x stock 10-4 M ascorbic acid and 1ng/mL TGF were added to the medium. Following the first treatment, ascorbic acid was added
every 2 days, and TGF- was added twice weekly either during media changes or directly
to the cells. Cells were taken at day 14 for qRT-PCR analysis. Endothelial tube formation
was performed by thawing concentrated Matrigel (Corning) overnight in a 4C
refrigerator on ice. The next day, pipette tips were cooled in -20C for 30 minutes and
used to plate 50µL of thawed matrigel in each well of a 96-well plate. Plated matrigel
was allowed to harden in a CO2 incubator for 30-60 minutes and 20,000 cells were plated
per well in 150µL EGM-2 + 10% FBS and incubated for an additional 5 hours. Cells
were washed twice with PBS and 3.75µL Calcein AM was added to 1mL of EGM-2. The
staining solution was added to each well and incubated for a final 30 minutes. Staining
medium was replaced with fresh EGM-2 +10% serum prior to imaging endothelial tubes
at the 4x objective using an EVOS imaging system (Arnaoutova et al., 2009). To induce
osteogenic differentiation, cells were cultured in DMEM +10% FBS supplemented with
50µM ascorbic acid, 10mM -glycerophosphate and 100nM dexamethasone. Medium
was changed twice weekly for 16 days, and cells were analyzed for qRT-PCR and flow
cytometry analysis for osteoblast markers, RUNX2, OPN, COL1A1, ALPL, and OCN, at
days 7 and 14-16 (Jaiswal et al., 1997, Sottile et al., 2003) (Figure 1).

Figure 1. Osteogenic differentiation by ascorbic acid, -glycerophosphate, and
dexamethasone treatment.
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RNA Extraction
RNAprotect (Qiagen, Valencia, CA) and TRIzol reagent (Life Technologies,
Grand Island, NY) were used to store cells. RNA was extracted from cells in RNAprotect
using the Qiagen RNeasy Kit. Cells were homogenized in TRIzol reagent and RNA was
isolated as per the manufacturer’s instructions. First strand cDNA synthesis was
performed from 2g total RNA using Superscript III Reverse Transcriptase (Invitrogen,
Grand Island, NY).

qRT-PCR Analysis
Quantitative RT-PCR was performed on a BioRad iQ5 Cycler as previously
described (Fuentes et al., 2013). PCR conditions were as follows: 94C for 10 minutes,
followed by cycles of 15 seconds at 94C for denaturation, annealing for 60 seconds at
56C, and extension for 30 seconds at 72C for a total of 40 cycles for most primer pairs.
Human primer pairs were designed using NCBI Primer Blast as well as taken from
previously published literature (Sottile et al., 2003). Fold changes were calculated using
the ΔΔCt method (Schmittgen et al., 2008). A list of primers that were used for qRT-PCR
analysis may be found in supplemental table 1 (Table S1).

Flow Cytometry
Following induction, cells were trypsinized, fixed with 4% paraformaldehyde, and
labeled with antibodies at concentrations recommended by the manufacturers. Cells for
osteoblast detection were labeled with mouse anti-human Osteocalcin Alexa Fluor 488
conjugated antibody (R&D Systems, MN). FACS analysis was performed on a
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MACSquant analyzer (Miltenyi Biotec, Auburn, CA). Forward- and side-scatter gating
was used to gate out any small particles and/or dead cells. FlowJo software (Ashland,
OR) was used for quantification.

Statistical Analysis
Data were processed using Microsoft Excel and Graphpad Prism 7.02 and expressed as
the mean  S.E.M. Data were tested for normality using the Sharpiro-Wilk normality test.
Statistical significance was determined using a Student’s t test for qRT-PCR analysis. Pvalues less than 0.05 were assumed to be significant.
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CHAPTER THREE
RESULTS

Human Neonatal CPCs Express a Distinct Set of Early Developmental Markers
Clonal populations of human neonatal cardiovascular progenitor cells coexpressing ISL1 and c-Kit were previously isolated and characterized for further use in
the laboratory (Fuentes et al., 2013). Phenotypic profiling revealed distinct populations of
neonatal CPCs expressing pre-cardiac mesoderm markers ISL1, KDR, and PDGFRa
(Fuentes et al., 2013). In order to investigate the developmental stage of the neonatal
CPC co-expressing ISL1, MESP1, KDR, and c-KIT, we performed gene expression
analysis on neonatal CPCs for molecular markers associated with the mesoderm.
All neonatal CPC clones that were examined for this study expressed the
pluripotency marker OCT4, as well as markers of the mesoderm and mesendoderm
including brachyury (T) and goosecoid (GSC), respectively. One of the clonal
populations of neonatal CPCs uniquely expressed demonstrable levels of MESP1, along
with its mesendodermal precursor, EOMES (Figure 2). This clone presented a gene
expression profile similar to that of a primitive cardiogenic cell population. Based upon
expression of early molecular markers associated with the mesoderm and pre-cardiac
mesoderm, we sought to assess the differentiation capacity of this MESP1+ neonatal CPC
(Figure 3). Previous studies have shown ISL1+/c-KIT+ co-expressing neonatal CPCs can
differentiate into cardiomyocyte and endothelial cells. Differentiation into the cardiac and
osteoblast lineage was performed on this ISL1+, c-KIT+, KDR+, and MESP1+ clone to
investigate the differentiation and multipotential capacity.
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Figure 2. mRNA analysis of molecular markers associated with mesoderm, precardiac
mesoderm, and cardiac progenitors. Relative mRNA expression of pluripotent marker,
OCT4, mesoderm (T, MIXL1, GSC, EOMES) and pre-cardiac mesoderm (MESP1, KDR,
PDGFRa) in the select ISL1+/c-KIT+/KDR+ and MESP1+ clone by RT-PCR and resolved
using an agarose gel.
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Figure 3. Summary of the stage-specific expression of molecular markers associated with
cardiovascular development. Blue text signifies activation. Sharp arrows represent
stimulatory effects; blunt arrows depict inhibitory effects.
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Differentiation of an ISL1+/c-KIT+ and MESP1+ Neonatal CPC into the Cardiac
Lineage
Cardiomyocyte differentiation was performed in order to confirm the
differentiation capacity of the ISL1+/c-KIT+/MESP1+/KDR+ neonatal CPC along the
cardiovascular lineage. The cardiomyocyte differentiation protocol was adapted from a
previous report involving treatment of human cardiomyocyte progenitor cells with 5azacytidine, TGF-, and ascorbic acid (Smits et al., 2009). In addition, an endothelial
tube formation assay was conducted to assess endothelial cell differentiation. Formation
of tubes has been shown to determine the capability of cells to differentiate along the
endothelial cell lineage (Arnaoutova et al., 2009). Endothelial cells respond to
proangiogenic signals and migrate rapidly to form capillary-like tubes when plated over
Matrigel (DeCicco-Skinner et al., 2014).
The ISL1+/c-KIT+/KDR+ and MESP1+ clone was capable of differentiation into
cardiomyocytes and endothelial cells. Cardiomyocyte differentiation was demonstrated
by a significant induction of the cardiomyogenic-specific transcript, Troponin T (TNNT2)
(Figure 4). Furthermore, the neonatal clone effectively formed tubes (Figure 5),
indicating that these cells have endothelial differentiation capacity. Following tube
network formation, cells were imaged and documented using an EVOS FL imaging
system set at the 4x objective.

15

Control
(TNNT2)

Treated
(TNNT2)

Figure 4. Differentiation of ISL1+/c-KIT+/MESP1+/KDR+ human neonatal CPC into
cardiomyocytes. After 14 days of culture in differentiation medium, gene expression levels
for Troponin T (TNNT2) were elevated in the neonatal CPC expressing markers of early
cardiovascular development (N=3, run in triplicate P < 0.05).
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Figure 5. Tube formation by the ISL1+/c-KIT+/ KDR+ and MESP1+ neonatal CPC clone
verifies differentiation along the endothelial cell lineage. Representative images of
endothelial cell tube formation over Matrigel in a select neonatal CPC exhibiting early
developmental characteristics. Scale bar = 1000 m (N = 3).
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A Neonatal CPC Co-Expressing ISL1, c-KIT, KDR and MESP1 Differentiates into a
Mature Osteoblast Phenotype
In order to assess the differentiation capacity of the early ISL1+/cKIT+/MESP1+/KDR+ neonatal CPC clone into mesodermal derivatives, differentiation
into the osteoblast lineage was performed. Neonatal CPCs were cultured in 6-well plates
at 5 x 103 cells per well in DMEM/10% FBS with osteogenic supplements, 50uM
ascorbic acid, 10mM -glycerophosphate and 100nM dexamethasone (Figure 6) (Bielby
et al., 2004; Jaiswal et al., 1997; Sottile et al., 2003). Dexamethasone acts to induce the
expression of the transcription factor, RUNX2, through a beta-catenin-mediated pathway,
while ascorbic acid and -glycerophosphate have been shown to play roles
predominantly in establishing the extracellular matrix by increasing collagen type 1
secretion and serving as a phosphate source, respectively (Langenbach et al., 2013).

Dexa, βglycerophosphate,
and ascorbic acid

Replace
differentiation
media every 2-3
days

Analysis of
osteogenic
markers at 7 and
14-16 days

Figure 6. Timeline of neonatal CPC differentiation into osteoblasts. Cells were expanded
in 6-well plates for 7 to 14/16 days.
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Osteogenic-specific molecular markers were analyzed by qRT-PCR following 7
days of induction which revealed a significant increase in the expression of early markers
of osteoblast differentiation (Figure 7). RUNX2, the most upstream transcription factor
essential for osteoblast differentiation (Komori, 2017), was found to be significantly
elevated (519-fold, P=0.01) following the initial induction period. Osteopontin (OPN),
one of the non-collagenous extracellular structural proteins secreted in the bone, has been
shown to behave bimodally, by which peak expression occurs during active proliferation,
decreases post-proliferatively, and peaks once more at the onset of mineralization (Lian
et al., 1995; Twine et al., 2014). Similar to these findings, OPN expression was
significantly induced in the neonatal CPC at the initial proliferative stages of osteoblast
differentiation (Figure 7A). Alkaline phosphatase (ALPL) and Collagen type 1 (COL1A1)
are important components for establishing the mineralized matrix present in bone (Stein
et al., 1993). Expression of both mineralization and extracellular matrix-related
transcripts were induced following 7 days of differentiation in osteogenic supplemented
media. OCN expression has been shown to occur at later stages of osteoblast
development and is reflective of a mature osteoblast phenotype (Lian et al., 1995; Ducy
et al., 1995; Huang et al., 2007). In order to confirm osteoblast lineage commitment, gene
and protein expression analyses of OCN were performed following 14-16 days of
osteoblast induction. The neonatal CPC demonstrated an increase in the expression of the
late-stage osteoblast marker by both qRT-PCR (Figure 8) and flow cytometry (Figure 9),
and therefore verified differentiation of the selected ISL1+/c-KIT+/KDR+ and MESP1+
neonatal CPC into a mature osteoblast phenotype. Differentiation into the osteoblast
lineage thereby confirms mutlipotential differentiation capability of this early progenitor.
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A

OPN

RUNX2

COL1A1

ALPL

B

RUNX2

COL1A1

Figure 7. Neonatal CPC co-expressing ISL1, c-KIT, KDR, and MESP1 treated with
osteogenic supplements for 7 days showed enhanced expression of osteogenic markers.
(A) Representative gene expression analysis of early developmental markers OPN (P ≤
0.01), RUNX2 (P ≤ 0.01), COL1A1 (P ≤ 0.0001), and ALPL (P ≤ 0.0001) following 7 days
of differentiation. (B) RUNX2 and COL1A1 expression was induced ~500 and ~900 fold,
respectively. Abbreviations: OPN, Osteopontin; OCN, Osteocalcin; Runx2, Runt related
transcription factor 2; Col1A1, Collagen Type 1; ALPL, Alkaline Phosphatase (N=3).
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Control
(OCN)

Treated
(OCN)

Figure 8. The ISL1+/c-KIT+/KDR+ and MESP1+ Neonatal CPC treated with osteogenic
supplements for 14-16 days showed enhanced expression of late-stage osteoblast
differentiation marker, osteocalcin. Expression of the transcript for osteocalcin (OCN) was
induced at 14-16 days of osteoblast differentiation (N=3, P <0.05).
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Figure 9. The ISL1+/c-KIT+/KDR+ and MESP1+ Neonatal CPC treated with osteogenic
supplements for 14-16 days showed enhanced expression osteocalcin by flow cytometry
(A) Forward and side scatter dot plot of untreated and treated CPCs. (B) Flow cytometry
histogram of increased OCN expression. Positive staining is represented by the colored
histogram, dotted histogram is representative of the isotype control (N=3).
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CHAPTER FOUR
DISCUSSION

In the present study, we demonstrated that neonatal CPCs isolated from the
human heart co-expressing MESP1, c-KIT, KDR, and ISL1 can be induced to differentiate
into various mesodermal lineages, including cardiovascular and bone. Differentiation into
the osteoblast lineage by neonatal cardiac progenitors expressing this array of early
developmental markers demonstrated enhanced multipotential capability. Osteoblasts, the
specialized mesenchymal cells that synthesize bone are, in addition to the cardiovascular
lineage, one of the mesodermal derivatives regulated by the Wnt-signaling pathway
(Bakre et al., 2007; Yavropoulou et al., 2007). A lineage tracing study in mice
demonstrated that development of the heart and hindlimb may be regulated by a common
pathway in Isl1-expressing progenitors (Yang et al., 2006). This early study supports the
concept that Isl1 marks a subset of heart and hindlimb progenitors, and Isl1 may be
upstream in common heart/hindlimb pathways (Yang et al., 2006). Similarly, human
cardiac progenitor cells expressing ISL1 have been reported to differentiate into the
osteoblast lineage, further demonstrating the multipotential capability of ISL1-expressing
progenitor populations. However, the findings from this group did not demonstrate
clonogenicity of progenitor cells, nor were the cell populations examined for coexpression of early developmental markers such as MESP1 and/or KDR that have been
reported in the current study. Furthermore, the cardiac progenitor cells investigated did
not exhibit an overlap between c-KIT and ISL1 expression (Itzhaki-Alfia et al., 2009).
Taken together, these findings support the novel concept that isolation of cells on the
basis of ISL1 and c-KIT coexpression selects for a subpopulation of cardiac progenitors
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with enhanced multipotential differentiation capacity, and that these cells may be
sustained within the mesendodermal stage of development.
The ISL1+/c-KIT+/MESP1+/KDR+ neonatal CPC expressed transcripts for
modulators of the mesendoderm, such as GSC, MIXL1, and EOMES, and therefore may
reside in a stage of development that is earlier than the pre-cardiac mesoderm. GSC is
strongly expressed in cell populations identified as mesendodermal regulators during the
formation of the anterior primitive streak (Blum et al., 1992; Tada et al., 2005), and
furthermore has been shown to be expressed in a majority of ISL1+/c-KIT+ neonatal CPCs
that were examined in the present study. The mesendoderm has been characterized as a
diverging point of the mesoderm and definitive endoderm during hESC differentiation
(Tada et al., 2005). Interestingly, MESP1 has been shown to be involved in the regulation
of the mesendodermal stage of embryogenesis (Soibam et al., 2015). Soibam and
colleagues identified early cell lineages regulated by MESP1, and found that MESP1
targets mesendoderm modulating markers, giving rise to progenitors of the mesoderm
and endoderm during gastrulation (Soibam et al., 2015). Several mesendoderm regulatory
factors that are activated by MESP1 include EOMES, GATA4, GSC, T, and MIXL1,
suggesting that this ISL1+/c-KIT+/MESP1+/KDR+ neonatal CPC resides within the
mesendodermal stage of development.
The bipotent mesendoderm has been established as a very early developmental
stage in many species, including C. elegans, drosophila, xenopus, and zebrafish
(Rodaway and Patient, 2001). Fate mapping experiments have demonstrated that
definitive endoderm progenitors are specified in close proximity to cardiovascular
progenitors (Costello et al., 2015). The close association between mesoderm and
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endoderm formation within the primitive streak in addition to the co-expression of
markers specific for mesoderm and endoderm precursors in early progenitor cells,
supports evidence of a common bipotential progenitor population originating at the onset
of gastrulation (Rodaway et al., 1999; Kimelman and Griffin, 2000). Moreover, these
reports suggest that a population of progenitor cells within this region may be capable of
differentiating into both mesodermal and endodermal lineages. Further research to define
the differentiation and regenerative properties of neonatal CPCs is ongoing.
The present study sought to identify a population of human neonatal CPCs with
enhanced differentiation and multipotential capability for applications in stem cell-based
regenerative therapy. Our findings demonstrate that the KDR+, MESP1+, ISl1+, and cKIT+ endogenous human neonatal CPC are associated with the early stages of embryonic
development and preserves characteristics of the mesendoderm, with the potential for
enhanced efficacy. Analysis of several ISL1+/c-KIT+ adult CPCs revealed expression of
transcripts for GSC, suggesting that the clonal populations from both neonatal as well as
adult sources co-expressing ISl1 and c-KIT sustain transcripts of the mesendoderm. These
exciting results provide valuable information regarding the identity of a cardiovascular
stem cell population that may be implemented as an optimal source for numerous stem
cell-based regenerative therapies. Future studies will focus on determining the
differentiation propensity of endogenous neonatal CPCs into the endodermal lineage to
verify the functionality of the expressed mesendodermal transcripts.
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SUPPLEMENTAL TABLES/FIGURES

Table S1. List of primers used to detect gene expression by qRT-PCR
Amplicon

Product
Size

TmFwd

TmRev

ACTIN

130bp

63

62

ALPL

543bp

62

59

BRACHYURY

568bp

67

66

C-KIT

105bp

63

62

COL1

461bp

57

59

EOMES

381bp

59

59

GATA4

189bp

58

59

GSC

158bp

60

59

ISL1

202bp

59

56

KDR

219bp

62

61

MESP1

377bp

60

60

MIXL1

501bp

57

60

NKX2-5

111bp

57

61

294bp

60

65

123bp

65

63

355bp

55

56

PDGFRA

496bp

62

61

RUNX2

460bp

60

59

TGFB1

384bp

60

60

TNNT2

131bp

59

57

OCN/
BGLAP
OCT4/
POU5F1
OPN/
SPP1

Forward and Reverse Sequence (5’-3’)

Fwd: TTTGAATGATGAGCCTTCGTCCCC
Rev: GGTCTCAAGTCAGTGTACAGGTAAGC
Fwd: GGGGGTGGCCGGAAATACAT
Rev: GGGGGCCAGACCAAAGATAG
Fwd: ACTGGATGAAGGCTCCCGTCTCCTT
Rev: CCAAGGCTGGACCAATTGTCATGGG
Fwd: ATTCCCAAGCCCATGAGTCCTTGA
Rev: ACACGTGGAACACCAACATCCT
Fwd: GGACACAATGGATTGCAAGG
Rev: TAACCACTGCTCCACTCTGG
Fwd: TTGAAAAAGGGCAGAAAGGCG
Rev: TTTGCAAAGCGCAGACGG
Fwd: GACAATCTGGTTAGGGGAAGC
Rev: ACACAATGCAAAACCCACGG
Fwd: AACGCGGAGAAGTGGAACAA
Rev: AGCATCGTCTGTCTGTGCAA
Fwd: CACAAGCGTCTCGGGATTGTGTTT
Rev: AGTGGCAAGTCTTCCGACAA
Fwd: CCTCTACTCCAGTAAACCTGATTGGG
Rev: TGTTCCCAGCATTTCACACTATGG
Fwd: CGCTATATCGGCCACCTGTC
Rev: GGCATCCAGGTCTCCAACAG
Fwd: TTTTCTCCCCTCTTCCAGGTA
Rev: CGTCATTGACAAAGTGGCGG
Fwd: CGCCGCTCCAGTTCATAG
Rev: GGTGGAGCTGGAGAAGACAGA
Fwd: ATGAGAGCCCTCACACTCCTC
Rev: GCCGTAGAAGCGCCGATAGGC
Fwd: AACCTGGAGTTTGTGCCAGGGTTT
Rev: TGAACTTCACCTTCCCTCCAACCA
Fwd: CATCTCAGAAGCAGAATCTCC
Rev: CCATAAACCACACTATCACCTC
Fwd: GCGCAATCTGGACACTGGGA
Rev: ATGGGGTACTGCCAGCTCAC
Fwd: CCTCAGTGATTTAGGGCGCA
Rev: GGTGTGGTAGTGAGTGGTGG
Fwd: GGGCTACCATGCCAACTTCT
Rev: GACACAGAGATCCGCAGTCC
Fwd: GTGGGAAGAGGCAGACTGAG
Rev: ATAGATGCTCTGCCACAGC
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